An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression
Author:
Affiliation:
1. Department of UrologyGunma University Hospital Japan
2. Department of UrologyGunma Prefectural Cancer Center Japan
3. Department of UrologyIsesaki Municipal Hospital Japan
4. Department of UrologyTatebayashi Kosei Hospital Japan
Publisher
Wiley
Subject
Urology,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23865
Reference28 articles.
1. Prostate cancer in Asian men
2. Novel agents for castration-resistant prostate cancer: Early experience and beyond
3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
4. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
5. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy;Annals of Nuclear Medicine;2024-04-22
2. Increase of prostate specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing [223Ra]RaCl2 therapy;2023-12-19
3. Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel;Journal of Urologic Oncology;2023-11-30
4. The utility of the [−2]pro‐prostate‐specific antigen level as a prognostic marker in patients with castration‐resistant prostate cancer treated with enzalutamide;International Journal of Urology;2023-05-31
5. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer;Annals of Oncology;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3